ライフサイエンスコーパス: platelet transfusion

1 Forty-nine patients (88%) did not require platelet transfusion.

2 adjustment for baseline characteristics and platelet transfusion.

3 ffects of ticagrelor cannot be reversed with platelet transfusion.

4 at 0.25 to 4 hours and 16 to 32 hours after platelet transfusion.

5 ransferred by bone marrow transplantation or platelet transfusion.

6 the chances of many of the complications of platelet transfusion.

7 he last dose of cyclophosphamide to the last platelet transfusion.

8 ical problem for which the main treatment is platelet transfusion.

9 , profound thrombocytopenia recurred despite platelet transfusion.

10 ho failed to achieve an adequate response to platelet transfusion.

11 Only 2 patients required more than one platelet transfusion.

12 vention, and management of refractoriness to platelet transfusion.

13 bone marrow failure, requiring prophylactic platelet transfusion.

14 nulocytopenic fever, and no patient required platelet transfusion.

15 basis of platelet function for prophylactic platelet transfusion.

16 ted adverse immune reactions associated with platelet transfusion.

17 d each patient's platelet count responded to platelet transfusion.

18 evere thrombocytopenia requiring one or more platelet transfusions.

19 uma resuscitation has shifted toward liberal platelet transfusions.

20 logy patients who received 6031 prophylactic platelet transfusions.

21 t approach for managing ABO compatibility in platelet transfusions.

22 cal trials of the optimal timing and dose of platelet transfusions.

23 usion practices, and adverse consequences of platelet transfusions.

24 cell concentrates), and 21 patients received platelet transfusions.

25 h aplastic anemia refractory to random donor platelet transfusions.

26 life-threatening bleeding episodes requiring platelet transfusions.

27 d significantly improve the effectiveness of platelet transfusions.

28 adverse event was recorded during autologous platelet transfusions.

29 se myelosuppression, and reduce the need for platelet transfusions.

30 emotherapy acquire thrombocytopenia and need platelet transfusions.

31 treatment with immunosuppressive agents and platelet transfusions.

32 ere thrombocytopenia and reduce the need for platelet transfusions.

33 quent incorporation of cytokines and RBC and platelet transfusions.

34 Peripheral blood counts and platelet transfusions.

35 ry interruption of abciximab infusions or to platelet transfusions.

36 red more days of intravenous antibiotics and platelet transfusions.

37 atients, both in the PIXY321 group, required platelet transfusions.

38 nic hematology/oncology patients in spite of platelet transfusions.

39 tions, schedule alterations, or the need for platelet transfusions.

40 let counts of less than 10 x 10(9) per L; or platelet transfusions.

41 tients receiving prophylactic or therapeutic platelet transfusions.

42 (3) control), average number of days to next platelet transfusion (1.9 PCT versus 2.4 control), and n

43 amino-8-D-arginine vasopressin (0.4 ug/kg) + platelet transfusion (2 U) within 60 minutes of intracer

44 surgery was associated with a higher risk of platelet transfusion (22.7% [5 of 22] vs 6.4% [12 of 187

45 at least two sequential ABO-compatible fresh platelet transfusions; (3) hepatomegaly is best defined

46 mination; and there was inappropriate use of platelet transfusions (41 with mild or moderate disease)

47 (1.9 PCT versus 2.4 control), and number of platelet transfusions (8.4 PCT versus 6.2 control) were

48 Platelet transfusion after acute spontaneous primary int

49 Keywords included platelet transfusion, alloimmunization, hemorrhage, thre

50 ith severe thrombocytopenia receive repeated platelet transfusions, although evidence of their clinic

51 23 (24%) participants assigned to platelet transfusion and 16 (17%) assigned to standard c

52 97 participants were randomly assigned to platelet transfusion and 93 to standard care.

53 opments in the area of ABO compatibility and platelet transfusion and examines the risks and benefits

54 ed for the continued use of prophylaxis with platelet transfusion and show the benefit of such prophy

55 It will also briefly address platelet transfusion and the role of glycans in the clea

56 ia occurred in 32% of patients; 63% received platelet transfusions and 58% required RBCs.

57 atients, which resulted in independence from platelet transfusions and absence of severe bleeding eve

58 Our data validate HLAMatchmaker for platelet transfusions and demonstrate its potential to r

59 Decreased number of red blood cell and platelet transfusions and in some cases transfusion inde

60 Number of platelet transfusions and incidence of IVH.

61 y to the above treatment plus daily multiple platelet transfusions and IV immunoglobulin.

62 strategy to minimise the risks of allogeneic platelet transfusions and provide a long-lasting supply

63 ematologic malignancy, resulting in frequent platelet transfusions and significant resource consumpti

64 Despite an increase in observed bleeding, platelet transfusion, and surgical re-exploration for bl

65 h an increased risk of early RBC, plasma and platelet transfusions, and fibrinolysis.

66 gorithm reduces red blood cell transfusions, platelet transfusions, and major bleeding following card

67 erienced more frequent hospitalization, more platelet transfusions, and more missed doses of chemothe

68 d were platelet increments, interval between platelet transfusions, and platelet refractoriness.

69 ion, year of therapy, sex, refractoriness to platelet transfusions, and previous treatment with andro

70 orrelated with low preoperative PLT, massive platelet transfusions, and re-transplantation.

71 marrow chimera, mast cell-deficient animals, platelets transfusion, and bone marrow dendritic cells (

72 Platelet transfusions are a crucial component of support

73 Low-dose prophylactic platelet transfusions are as effective in the prevention

74 Platelet transfusions are associated with higher odds of

75 Platelet transfusions are commonly used to prevent bleed

76 Platelet transfusions are life-saving treatments for man

77 onents such as fresh frozen plasma (FFP) and platelet transfusions are limited.

78 Platelet transfusions are now the cornerstone for treati

79 Platelet transfusions are often a life-saving interventi

80 Platelet transfusions are required to prevent the potent

81 Red blood cell (RBC) and platelet transfusions are the mainstays of therapy, but

82 ting both the safety and efficacy of liberal platelet transfusions are warranted.

83 row transplant patients who require multiple platelet transfusions as a consequence of post-transplan

84 s (296 of 328 infants) received at least one platelet transfusion, as compared with 53% (177 of 331 i

85 nia starting on day 15 of the first cycle or platelet transfusion at any time during the 4-cycle trea

86 Prophylactic platelet transfusion at defined platelet count threshold

87 vere thrombocytopenia developed to receive a platelet transfusion at platelet-count thresholds of 50,

88 ntation at experienced centers may receive a platelet transfusion at the first sign of bleeding, rath

89 cers or solid tumors to receive prophylactic platelet transfusions at a low dose, a medium dose, or a

90 after randomization than those who received platelet transfusions at a platelet-count threshold of 2

91 ytopenia, those randomly assigned to receive platelet transfusions at a platelet-count threshold of 5

92 Patients refractory to platelet transfusions because of alloimmunization requir

93 The primary end point was the avoidance of a platelet transfusion before, during, and up to 7 days af

94 half to twice the usual dose of 2.2 x 10(11) platelets/transfusion/body surface area (BSA) do not aff

95 half to twice the usual dose of 2.2 x 10(11) platelets/transfusion/BSA have no affect on WHO bleeding

96 with aspirin alone was associated with more platelet transfusion but similar degree of bleeding; in

97 8(+) T cells are required for priming during platelet transfusion, but only CD8(+) T cells are requir

98 bopoietin agonists are a good alternative to platelet transfusion, but require time (about 10 days) t

99 However, platelet transfusion can transmit infections and trigger

100 Platelet transfusion cannot be recommended for this indi

101 10(9)/L has become accepted for prophylactic platelet transfusions, care should be taken to ensure th

102 atelet counts and thereby delay time to next platelet transfusion compared to routinely available pla

103 n nonmyeloablative transplants, 23% required platelet transfusions compared with 100% among patients

104 The estimated average 60-day platelet transfusion cost per patient was $4,000 for aut

105 m cells (PBSC) had faster recovery and fewer platelet transfusion days than recipients of bone marrow

106 predicted longer periods of neutropenia and platelet transfusion dependence (P <or=.03).

107 er L; had 10-50% bone-marrow blasts; or were platelet transfusion dependent were randomly assigned (2

108 od cell transfusion-dependent and 53 (40.2%) platelet transfusion-dependent patients achieved transfu

109 contaminated platelets are a major hazard of platelet transfusion despite recent interventions.

110 Refractoriness to platelet transfusions developed in 27% of the patients.

111 randomized clinical trial that prophylactic platelet transfusion did not reduce clinical bleeding.

112 icant clinical factors and thrombocytopenia, platelet transfusions did not have a significant effect

113 did not correlate with the risk for IVH, and platelet transfusions did not reduce this risk.

114 In patients with poor platelet recovery, platelet transfusion does not improve outcomes and may a

115 Daily platelet transfusion dose was independently associated w

116 Patients in group A received platelet transfusions during implantation.

117 P guided by CCA and utilizes less plasma and platelet transfusions during the early phase of resuscit

118 For preoperative PLT, platelet transfusions during the operation, re-transplan

119 t it is unclear whether these factors impact platelet transfusion efficacy on clinical bleeding.

120 Untreated platelet transfusions elicited strong IgG responses that

121 The AABB suggests platelet transfusion for patients having bypass who exhi

122 MMENDATION 2: The AABB suggests prophylactic platelet transfusion for patients having elective centra

123 MMENDATION 3: The AABB suggests prophylactic platelet transfusion for patients having elective diagno

124 MMENDATION 4: The AABB suggests prophylactic platelet transfusion for patients having major elective

125 6: The AABB cannot recommend for or against platelet transfusion for patients receiving antiplatelet

126 AABB recommends against routine prophylactic platelet transfusion for patients who are nonthrombocyto

127 Days of platelet support and number of platelet transfusions for patients with ALI were not sig

128 n the < or = 20,000/microL arm received more platelet transfusions for prophylactic indications [10 (

129 ons also induced tolerance to subsequent STD platelet transfusions from the same donor (82% acceptanc

130 We performed secondary analyses of platelet transfusions given in the prospective randomize

131 Nevertheless, the total number of platelet transfusions given to patients on the < or = 20

132 d high vs. medium), but the median number of platelet transfusions given was significantly higher in

133 or dependence at 3 months were higher in the platelet transfusion group than in the standard care gro

134 eline updates and replaces the previous ASCO platelet transfusion guideline published initially in 20

135 these questions in order to provide optimal platelet transfusion guidelines.

136 40 (42%) participants who received platelet transfusion had a serious adverse event during

137 n a life-saving intervention, and the use of platelet transfusions has been increasing.

138 both the blood platelet counts that prompt a platelet transfusion (i.e. trigger) in various clinical

139 16 320 patient-days on or after their first platelet transfusion in 1077 adult patients enrolled in

140 ding from childhood, requiring >/=1 blood or platelet transfusion in 78% of cases.

141 veloped this guideline on appropriate use of platelet transfusion in adult patients.

142 ults suggest no hemostatic efficacy of early platelet transfusion in intracerebral hemorrhage under a

143 Other recommendations address platelet transfusion in patients with hematologic malign

144 rovide evidence-based guidance on the use of platelet transfusion in people with cancer.

145 levated by thrombocytopenia and decreased by platelet transfusion in septic mice.

146 ne Guidelines (the use of leukoreduction and platelet transfusion in solid tumors or chronic, stable

147 rehospital use of iron or erythropoietin and platelet transfusion in the ICU were independently assoc

148 development of evidence-based protocols for platelet transfusion in the newborn and stimulate contin

149 change to a previous recommendation involved platelet transfusion in the setting of hematopoietic ste

150 The need for platelet transfusion in this group was reduced from 75%

151 Therefore, the precise role and triggers for platelet transfusion in trauma have yet to be fully char

152 spective studies show that early high-volume platelet transfusion in trauma may be associated with si

153 the current evidence for the use of FFP and platelet transfusions in critically ill patients.

154 There is little consensus on optimal platelet transfusions in either civilian or military pra

155 aberrant activity in trauma and the role of platelet transfusions in exsanguinating haemorrhage.

156 The need for platelet transfusions in four cycles was significantly l

157 Platelet transfusions in HIT were associated with higher

158 riability in use of allogeneic RBC, FFP, and platelet transfusions in patients undergoing major nonca

159 etic growth factor, in reducing the need for platelet transfusions in patients who undergo dose-inten

160 Eltrombopag reduced the need for platelet transfusions in patients with chronic liver dis

161 als compared different doses of prophylactic platelet transfusions in patients with haematological ma

162 ng platelet counts and reducing the need for platelet transfusions in patients with thrombocytopenia

163 idance regarding thresholds for prophylactic platelet transfusions in preterm neonates with severe th

164 sol treatment to prevent alloimmunization by platelet transfusions in rats.

165 and may lead to decreased intervals between platelet transfusions in thrombocytopenic patients.

166 ilable on risks and benefits associated with platelet transfusions in thrombotic thrombocytopenic pur

167 Platelet transfusions in TTP were associated with higher

168 ation, fever, bleeding, increasing number of platelet transfusions, increasing weight, at least 2 pre

169 Platelet transfusion increments were assessed at 0.25 to

170 neutrophil count of 0.5 x 10(9) cells/L and platelet transfusion independence were 17 and 16 days, r

171 lasts were < 5% with neutrophil recovery and platelet transfusion independence) that lasted a median

172 emission, hematologic improvement, or RBC or platelet transfusion independence) was 35% in previously

173 Duration of platelet transfusion independence, duration of response,

174 cytopenia was common, with failure to become platelet-transfusion independent in nine patients.

175 ibodies in refractory thrombocytopenia (post platelet transfusion), indicating that the level of fuco

176 atelet preparations, the use of prophylactic platelet transfusions, indications for transfusion in se

177 Herein, we perform a mechanistic analysis of platelet transfusion-induced BMT rejection and report th

178 In addition, allogeneic platelet transfusions into SCID mice with established CD

179 Poor response to platelet transfusion is a clinically and financially sig

180 e of ABO blood group system compatibility in platelet transfusion is a subject of ongoing debate.

181 Platelet transfusion is a very common lifesaving medical

182 Platelet transfusion is common in dengue patients with t

183 Prophylactic platelet transfusion is not necessary in children with p

184 Platelet transfusion is often used to restore hemostasis

185 t a 10,000/microL threshold for prophylactic platelet transfusion is safe and effective in uncomplica

186 Platelet transfusion is the most commonly used therapy b

187 go lumbar puncture (LP) without prophylactic platelet transfusion is unknown.

188 platelet donors on patient outcome following platelet transfusion is unknown.

189 e the evidence for a benefit of prophylactic platelet transfusions is weak and controversial.

190 fetal blood sampling (FBS) and intrauterine platelet transfusions (IUPT), as well as weekly maternal

191 standard (</=10 x 109/L), but required more platelet transfusions (low-quality evidence).

192 r platelets in septic shock and suggest that platelet transfusion may be effective in treating severe

193 This approach to platelet transfusion may be particularly important when

194 g allogeneic SCT or chemotherapy and because platelet transfusions may not prevent bleeding, other ri

195 al age, 28.2 [2.9] weeks), 231 received 1002 platelet transfusions (mean [SD], 4.3 [6.0] per infant;

196 Nine patients no longer needed platelet transfusions (median increase in platelet count

197 While platelet transfusion might be indicated in patients with

198 In a dog platelet transfusion model, we have evaluated other meth

199 5) was seen over six cycles after autologous platelet transfusions (n=63).

200 ny patients having an inadequate response to platelet transfusions, new strategies are needed to trea

201 more likely to bleed if given a prophylactic platelet transfusion (odds ratio 2.34, 95% confidence in

202 The effect of platelet transfusions on IGF-1R was explored.

203 3.9), septicemia (OR, 1.8; 95% CI, 1.2-2.6), platelet transfusion (OR, 6.4; 95% CI, 3.2-12.4), and re

204 antibody positivity, an increasing number of platelet transfusions, or receiving heparin or amphoteri

205 as superior to platelet count for predicting platelet transfusion (P < 0.001); and LY-30 (rate of amp

206 ith fewer patients (P =.014) receiving fewer platelet transfusions (P =.001) than patients receiving

207 ts (P =.016), a lower duration of pretherapy platelet transfusions (P =.013), and higher pretherapy p

208 and there exists a significant variation in platelet transfusion practice between centers.

209 t Sample to evaluate the current in-hospital platelet transfusion practices and their association wit

210 yeloablative therapy, controversies surround platelet transfusion practices.

211 sure to alloantigens during transplantation, platelet transfusion primes alloimmunity but does not st

212 Platelet transfusions provide transient benefit and are

213 Platelet transfusion provides an important therapeutic i

214 Allogenic platelet transfusions (PT) are administered to treat exc

215 Overall FFP and platelet transfusion rates were 8.9% and 3.8%, respectiv

216 has been used as a trigger for prophylactic platelet transfusions rather than the morning platelet c

217 e factors, preoperative PLT, intra-operative platelet transfusions, re-transplantation, and early rej

218 0(9)/L or more platelets or in the number of platelet transfusions received.

219 atients receiving red blood cells or plasma, platelet transfusion recipients are at a greater risk fo

220 ess ABH antigens, which can adversely effect platelet transfusion recovery and survival in ABH-incomp

221 g. neonatal allo-immune thrombocytopenia and platelet transfusion refractoriness) the causative idiot

222 Some will exhibit platelet transfusion refractoriness, defined as inapprop

223 s technique has not been widely described in platelet transfusion refractory bone marrow transplant p

224 0.98; P=0.02; number needed to treat, 24.7), platelet transfusion (relative risk, 0.77; 95% confidenc

225 data are the highest rate of acceptance for platelet transfusions reported in either animals or man.

226 11 significantly reduced the total number of platelet transfusions required in the assessable subgrou

227 bin III and protein C and an increase in the platelet transfusion requirement.

228 e duration of severe thrombocytopenia or the platelet transfusion requirement.

229 Red blood cell (RBC) and platelet transfusion requirements in patients given nonm

230 tropenia, incidences of febrile neutropenia, platelet transfusion requirements, and numbers of platel

231 The preoperative PLT, intra-operative platelet transfusion requirements, cross-match, recipien

232 platelet levels and a resultant decrease in platelet transfusion requirements.

233 nd the only significant predictor of RBC and platelet transfusion requirements.

234 creased platelet counts, and ten had reduced platelet transfusion requirements.

235 Platelet transfusion seems inferior to standard care for

236 rce utilization in order to identify optimal platelet transfusion strategies.

237 e the risk-benefit ratio of a liberal FFP or platelet transfusion strategy for critically ill patient

238 evaluating a restrictive vs. liberal FFP or platelet transfusion strategy for nonbleeding patients i

239 nd thrombopoiesis and to develop a potential platelet transfusion strategy that is not dependent upon

240 results of a therapeutic vs. a prophylactic platelet-transfusion strategy in acute myeloblastic leuk

241 Platelet transfusion studies demonstrate that platelet-d

242 Bone marrow transplantation and platelet transfusion studies demonstrated that platelet

243 Despite the reliance on platelet transfusion support in patients receiving myelo

244 wing within the screening period of 4 weeks: platelet transfusion, symptomatic bleeding, or platelet

245 For platelet transfusion, the American Society of Clinical O

246 the 1272 patients who received at least one platelet transfusion, the primary end point was observed

247 Evidence-based guidelines for platelet transfusion therapy in these patients are yet t

248 Currently platelet transfusion therapy is limited by several conce

249 lection in the 1960s laid the groundwork for platelet transfusion therapy on a scale not previously p

250 fication" approach enabled much wider use of platelet transfusion therapy until alternative means of

251 elets, this strategy may be a substitute for platelet transfusion therapy.

252 let transfusion requirements, and numbers of platelet transfusions; they also received induction chem

253 unexpected overall benefit of a prophylactic platelet transfusion threshold of 25 x 109/L compared wi

254 Specific platelet transfusion thresholds are based on the presenc

255 tion trial comparing two common prophylactic platelet transfusion thresholds in patients undergoing i

256 ly available data regarding neonatal RBC and platelet transfusion thresholds, as well as the potentia

257 We conducted a trial of prophylactic platelet transfusions to evaluate the effect of platelet

258 al platelet count threshold for prophylactic platelet transfusions to minimize bleeding, platelet use

259 The effectiveness of platelet transfusions to prevent bleeding in patients wi

260 that US neonatologists frequently administer platelet transfusions to VLBW infants with mild to moder

261 Platelet transfusions total >2.17 million apheresis-equi

262 A platelet transfusion trigger of </= 5 x 10(3)/muL may be

263 In line with the randomized Platelet Transfusion Versus Standard Care After Acute St

264 east 2 days before surgery, the incidence of platelet transfusion was 12.4% (24 of 193) in the ticagr

265 A platelet transfusion was avoided in 104 of 145 patients

266 h thrombocytopenia (PCT, <100000/muL) when a platelet transfusion was given compared with 113 of 190

267 t-days (59.5%) with thrombocytopenia when no platelet transfusion was given.

268 eeding classifications, but the incidence of platelet transfusion was higher in the ticagrelor group

269 nt with 1-deamino-8-D-arginine vasopressin + platelet transfusion was not associated with the 3-month

270 The incidence of platelet transfusions was 46%, 36%, and 69%, respectivel

271 whether a policy of not giving prophylactic platelet transfusions was as effective and safe as a pol

272 The incidence of bleeding events and platelet transfusions was less common among patients who

273 r insertion, and apheresis and a median of 9 platelet transfusions was required during hematopoietic

274 A median of 2 platelet transfusions was required for stem cell mobiliz

275 teria for 8 consecutive weeks independent of platelet transfusions) was achieved by 19 patients (46%)

276 Mean INR and platelet triggers for FFP and platelet transfusions were 1.9 +/- 1.3 and 60000 +/- 440

277 nt difference in the number of days on which platelet transfusions were administered among the 3 grou

278 adjusted odds ratios (adjOR) associated with platelet transfusions were calculated.

279 Until recently, prophylactic platelet transfusions were commonly given at a trigger o

280 Platelet transfusions were given in 16 pregnancies.

281 During that period, platelet transfusions were given on 35 of 53 days (66.0%

282 A large proportion of platelet transfusions were given to VLBW infants with PC

283 Platelet transfusions were reported in 10.1% TTP, 7.1% H

284 No red blood cell or platelet transfusions were required, and no complication

285 Ever since platelet transfusions were shown to reduce mortality fro

286 Mean platelet transfusions were significantly decreased from

287 Preoperative need for red blood cell and platelet transfusions were the most significant risk fac

288 to receive, or not to receive, prophylactic platelet transfusions when morning platelet counts were

289 tle information is available on the value of platelet transfusion where the absolute count is less th

290 e recent research on the use of prophylactic platelet transfusions, which is a topic that still provo

291 platelet count of more than 20,000 required platelet transfusions while receiving therapy.

292 e procedures are established indications for platelet transfusions, while the evidence for a benefit

293 body-mediated ITP is resistant to allogeneic platelet transfusions, while the T-cell-mediated form of

294 When indicated, platelet transfusion will raise the platelet count to sa

295 dose and the threshold at which prophylactic platelet transfusions will be most effective.

296 We aimed to investigate whether platelet transfusion with standard care, compared with s

297 9) per L) or grade 4 thrombocytopenia before platelet transfusion, with 25 x 10(9) platelets per L or

298 e either standard care or standard care with platelet transfusion within 90 min of diagnostic brain i

299 4 thrombocytopenia (59% v 9%; P < .0001) and platelet transfusions without bleeding (35% v 0%; P = .0

300 101 of 530 participants became refractory to platelet transfusions without evidence of HLA or human p